Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-08-11 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Cellid' (주식회사 셀리드) covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial and operational information, including company overview, business activities, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-11 Korean
[기재정정]증권신고서(지분증권) (2023.08)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Amendment to Securities Registration Statement) filed by Cellid Co., Ltd. It details specific amendments to a previously submitted securities registration statement, including updates to financial data following the submission of a semi-annual report and adjustments to issuance terms. This is a formal regulatory filing required by the Financial Supervisory Service (FSS) in South Korea for companies undergoing public offerings or capital changes. It does not fit into the specific categories like '10-K' (Annual Report) or 'IR' (Interim Report) as it is a registration amendment, and it is not a simple announcement of a report (RPA). Therefore, it is classified as a Regulatory Filing.
2023-08-11 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 1,000 characters) regarding the scheduling and details of an upcoming Investor Relations (IR) event. It provides the date, time, location, and purpose of the meeting, and mentions that materials will be posted on the company website and the Korea Exchange (KIND) system. Since it is an announcement of an event rather than the presentation slides themselves, and it serves as a regulatory notification of corporate activity, it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing an IR event, RPA is the most accurate classification.
2023-08-10 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding the scheduling and logistics of an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the meeting, and mentions that materials will be posted on the company website. Since it is an announcement of an event rather than the presentation slides themselves, and it is under 5,000 characters, it falls under the category of a Report Publication Announcement or general regulatory filing regarding corporate events.
2023-08-10 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정)(COVID-19 예방 백신 AdCLD-CoV19-1 OMI의 제3상 임상시험 계획(IND) 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Cellid) regarding the approval of a Phase 3 clinical trial for a COVID-19 vaccine. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it is a formal regulatory announcement of a material event (clinical trial approval) and does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2023-07-21 Korean
투자설명서
Capital/Financing Update Classification · 100% confidence The document is a '투자설명서' (Investment Prospectus) for Cellid Co., Ltd., detailing a capital increase (rights offering/public offering). It includes specific details such as the number of shares, offering price, subscription period, and payment date. It also contains a comprehensive 'Key Investment Risks' section, which is a standard requirement for a formal securities registration statement/prospectus. This document is a primary regulatory filing for capital raising, not an announcement of a report or a simple earnings release.
2023-07-17 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.